Figure 6: Rituximab enhances SF1126 induced apoptosis in aggressive B-NHL. SUDHL-4 and TMD-8 cells were untreated or treated with 10 µM SF1126, 10 µM CAL-101,20 µg/ml of rituximab alone and combinations as indicated for 48 hr. Apoptosiswas evaluated by flow cytometry after Annixin V and PI staining.The graph represents the mean percentage of apoptosis ± S.D. (n = 3).